• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据组织学模式分析 Epstein-Barr 病毒相关胃癌的遗传特征和 PD-L1 表达。

Genetic landscape and PD-L1 expression in Epstein-Barr virus-associated gastric cancer according to the histological pattern.

机构信息

Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.

Department of Biomedical Convergence Science and Technology, Kyungpook National University, Daegu, Republic of Korea.

出版信息

Sci Rep. 2023 Nov 9;13(1):19487. doi: 10.1038/s41598-023-45930-6.

DOI:10.1038/s41598-023-45930-6
PMID:37945587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10636116/
Abstract

Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC) is a distinct molecular subtype of gastric cancer. This study aims to investigate genomic and clinicopathological characteristics of EBVaGC according to the histological pattern. We retrospectively collected 18 specimens of surgically resected EBVaGCs. Whole-exome sequencing was performed for all cases. Moreover, PD-L1 expression and tumor-infiltrating lymphocyte (TIL) percentage were investigated. Among 18 EBVaGCs, 10 cases were of intestinal histology, 3 were of poorly cohesive histology, and the remaining 5 were of gastric carcinoma with lymphoid stroma histology. Whole-exome sequencing revealed that EBVaGCs with intestinal histology harbored pathogenic mutations known to frequently occur in tubular or papillary adenocarcinoma, including TP53, KRAS, FBXW7, MUC6, ERBB2, CTNNB1, and ERBB2 amplifications. One patient with poorly cohesive carcinoma histology harbored a CDH1 mutation. Patients with EBVaGCs with intestinal or poorly cohesive carcinoma histology frequently harbored driver mutations other than PIK3CA, whereas those with EBVaGCs with gastric carcinoma with lymphoid stroma histology lacked other driver mutations. Moreover, the histological pattern of EBVaGCs was significantly associated with the levels of TILs (P = 0.005) and combined positive score (P = 0.027). In conclusion, patients with EBVaGCs with different histological patterns exhibited distinct genetic alteration, PD-L1 expression, and degree of TILs.

摘要

EB 病毒(EBV)相关胃癌(EBVaGC)是一种独特的胃癌分子亚型。本研究旨在根据组织学模式研究 EBVaGC 的基因组和临床病理特征。我们回顾性收集了 18 例手术切除的 EBVaGC 标本。对所有病例均进行全外显子组测序。此外,还研究了 PD-L1 表达和肿瘤浸润淋巴细胞(TIL)百分比。在 18 例 EBVaGC 中,10 例为肠型组织学,3 例为低黏附组织学,其余 5 例为富含淋巴细胞的胃癌组织学。全外显子组测序显示,具有肠型组织学的 EBVaGC 存在已知在管状或乳头状腺癌中频繁发生的致病性突变,包括 TP53、KRAS、FBXW7、MUC6、ERBB2、CTNNB1 和 ERBB2 扩增。1 例低黏附型癌组织学患者存在 CDH1 突变。具有肠型或低黏附型癌组织学的 EBVaGC 患者常存在除 PIK3CA 以外的驱动突变,而具有富含淋巴细胞的胃癌组织学的 EBVaGC 患者则缺乏其他驱动突变。此外,EBVaGC 的组织学模式与 TIL 水平(P=0.005)和联合阳性评分(P=0.027)显著相关。总之,具有不同组织学模式的 EBVaGC 患者表现出明显不同的遗传改变、PD-L1 表达和 TIL 程度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/d2858c87d686/41598_2023_45930_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/467cc59ed588/41598_2023_45930_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/d9c5d64f3003/41598_2023_45930_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/cab5a494890b/41598_2023_45930_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/b247df3d7a36/41598_2023_45930_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/d2858c87d686/41598_2023_45930_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/467cc59ed588/41598_2023_45930_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/d9c5d64f3003/41598_2023_45930_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/cab5a494890b/41598_2023_45930_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/b247df3d7a36/41598_2023_45930_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2284/10636116/d2858c87d686/41598_2023_45930_Fig5_HTML.jpg

相似文献

1
Genetic landscape and PD-L1 expression in Epstein-Barr virus-associated gastric cancer according to the histological pattern.根据组织学模式分析 Epstein-Barr 病毒相关胃癌的遗传特征和 PD-L1 表达。
Sci Rep. 2023 Nov 9;13(1):19487. doi: 10.1038/s41598-023-45930-6.
2
Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers.STING 和 PD-L1 表达的预后展望及其与 Epstein-Barr 病毒相关胃癌预后的相关性。
Gut Liver. 2022 Nov 15;16(6):875-891. doi: 10.5009/gnl210359. Epub 2022 May 25.
3
Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.EBV 相关胃癌的免疫景观:来自西方学术机构的分析。
J Surg Res. 2024 Apr;296:742-750. doi: 10.1016/j.jss.2024.01.043. Epub 2024 Feb 17.
4
Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.EBV 阳性胃癌:免疫治疗的一个独特候选亚型。
J Surg Res. 2021 May;261:130-138. doi: 10.1016/j.jss.2020.12.029. Epub 2021 Jan 8.
5
The genomic architecture of EBV and infected gastric tissue from precursor lesions to carcinoma.EBV 病毒和癌前病变到癌组织的基因组结构。
Genome Med. 2021 Sep 7;13(1):146. doi: 10.1186/s13073-021-00963-2.
6
Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.EB 病毒相关胃癌免疫基因的转录分析及其与临床结局的关系。
Gastric Cancer. 2018 Nov;21(6):1064-1070. doi: 10.1007/s10120-018-0851-9. Epub 2018 Jun 18.
7
Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.PIK3CA、JAK2、PD-L1和PD-L2在爱泼斯坦-巴尔病毒相关胃癌中的表达及预后作用
Hum Pathol. 2016 Jul;53:25-34. doi: 10.1016/j.humpath.2016.02.007. Epub 2016 Mar 4.
8
Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.EBV 阴性伴有淋巴间质的胃癌预后不良与免疫表型相关。
Gastric Cancer. 2018 Nov;21(6):925-935. doi: 10.1007/s10120-018-0820-3. Epub 2018 Apr 7.
9
Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas.爱泼斯坦-巴尔病毒基因在爱泼斯坦-巴尔病毒相关胃癌中的表达。
World J Gastroenterol. 2005 Feb 7;11(5):629-33. doi: 10.3748/wjg.v11.i5.629.
10
Epstein-Barr virus-associated gastric cancer: A distinct subtype.EBV 相关胃癌:一种独特的亚型。
Cancer Lett. 2020 Dec 28;495:191-199. doi: 10.1016/j.canlet.2020.09.019. Epub 2020 Sep 23.

本文引用的文献

1
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach.《2022年韩国胃癌诊疗指南:基于证据的多学科方法》
J Gastric Cancer. 2023 Jan;23(1):3-106. doi: 10.5230/jgc.2023.23.e11.
2
Gastric cancer with Epstein-Barr virus heterogeneity: Evaluation of the frequency, clinicopathologic features, and genomic profiles.伴有爱泼斯坦-巴尔病毒异质性的胃癌:频率、临床病理特征及基因组图谱评估
Pathol Res Pract. 2022 Oct;238:154108. doi: 10.1016/j.prp.2022.154108. Epub 2022 Sep 6.
3
Epstein-Barr Virus and PD-L1 in Esophageal and Esophagogastric Junction Cancer: Differences According to Location and Histological Type.
爱泼斯坦-巴尔病毒与食管及食管胃交界癌中的程序性死亡受体配体1:根据位置和组织学类型的差异
J Gastrointest Surg. 2022 Nov;26(11):2358-2364. doi: 10.1007/s11605-022-05377-y. Epub 2022 Jun 6.
4
Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers.STING 和 PD-L1 表达的预后展望及其与 Epstein-Barr 病毒相关胃癌预后的相关性。
Gut Liver. 2022 Nov 15;16(6):875-891. doi: 10.5009/gnl210359. Epub 2022 May 25.
5
Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.在日本,晚期胃和食管胃交界腺癌患者的 PD-L1 蛋白表达、EBV 阳性和 MSI 状态的临床病理特征。
Cancer Biol Ther. 2022 Dec 31;23(1):191-200. doi: 10.1080/15384047.2022.2038002.
6
Targeting KRAS G12C mutation in lung adenocarcinoma.针对肺腺癌中的KRAS G12C突变
Lung Cancer. 2022 Mar;165:28-33. doi: 10.1016/j.lungcan.2021.12.021. Epub 2021 Dec 31.
7
ASTE1 frameshift mutation triggers the immune response in Epstein-Barr virus-associated gastric cancer.ASTE1移码突变引发爱泼斯坦-巴尔病毒相关胃癌的免疫反应。
Signal Transduct Target Ther. 2022 Jan 5;7(1):4. doi: 10.1038/s41392-021-00771-5.
8
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.一线纳武利尤单抗联合化疗与单纯化疗治疗晚期胃癌、胃食管交界癌和食管腺癌(CheckMate 649):一项随机、开放标签的3期试验。
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
9
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.生物标志物靶向治疗晚期胃癌和胃食管交界癌:一种新兴模式。
Nat Rev Clin Oncol. 2021 Aug;18(8):473-487. doi: 10.1038/s41571-021-00492-2. Epub 2021 Mar 31.
10
Epstein-Barr virus-associated gastric cancer: A distinct subtype.EBV 相关胃癌:一种独特的亚型。
Cancer Lett. 2020 Dec 28;495:191-199. doi: 10.1016/j.canlet.2020.09.019. Epub 2020 Sep 23.